Dechra Veterinary Products has announced that it will add two new antibiotics to treat respiratory infections in cats and a range of bacterial infections in dogs to its antibiotic portfolio from December.
Spizobactin is indicated for the treatment of (peri)oral and periodontal multi-bacterial infections in dogs such as those associated with gingivitis, stomatitis, glossitis, periodontitis, tonsillitis, dental fistula and other fistulous wounds in the oral cavity. Spizobactin has the active ingredients: spiramycin and metronidazole, and will be available in three different tablet strengths.
Doxybactin, a second generation tetracycline, can be used to target conditions caused by bacteria sensitive to doxycycline such as rhinitis, bronchopneumonia and interstitial nephritis in dogs and respiratory infections in cats. It will be available in multiple tablet strengths of 50mg, 200mg and 400mg.
Both treatments will be available with Dechra’s innovative SmartTab technology that is designed to encourage the effective and responsible use of antibiotics. Dechra states that the easy double divisibility of SmartTab ensures accurate and flexible dosing to help avoid development of antibiotic resistance associated with under dosing and the natural meat flavouring encourages acceptance to ensure the full course is completed.
Dechra Brand Manager Carol Morgan said: “The launch of Spizobactin and Doxybactin to the UK and ROI markets will offer vets even more choice when it comes to the targeted and responsible use of antibiotics for these specific conditions. Our innovative SmartTab technology is helping to play a major role in the effective use of antibiotics.
“Spizobactin and Doxybactin join other products including Metrobactin, the first veterinary-licensed metronidazole tablet for anaerobic infections, and Amoxibactin, an amoxicillin tablet for urinary, reproductive and airway infections, in our wider antibiotic portfolio that offers vets a range of options in their day to day practice.”
